Genes Environment and Behaviour Laboratory

Our research includes models of specific neurological conditions (e.g. Huntington's disease and other dementias) and psychiatric disorders, including autism, schizophrenia, depression, and anxiety disorders. We investigate behavioural, cellular and molecular levels in order to identify pathogenic mechanisms and novel therapeutic targets.

By integrating wide-ranging expertise (including animal behaviour, electrophysiology and molecular/cellular skills) and an extended network, the Genes Environment & Behaviour Laboratory explores how genes and environment combine via experience-dependent plasticity in the healthy and diseased brain.

More specifically, our group has been focusing on projects related to the gene–environment interaction modulating the pathophysiology of Huntington’s disease as well as studying the environmental (e.g. exercise) and pharmacological modulation of behaviours relevant to depression, anxiety and schizophrenia.

Recent publications include:

  1. Mo C, Hannan AJ, Renoir T. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease. Neurosci Biobehav Rev. 2015 May;52:178-92. (PMID: 25770041).
  2. Wright DJ, Renoir T, Smith ZM, Frazier AE, Francis PS, Thorburn DR, McGee SL, Hannan AJ, Gray LJ. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease. Transl Psychiatry. 2015 Jan 6;5:e492. (PMID: 25562842).
  3. Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice. Neurobiol Dis. 2014 Sep;69:248-62. (PMID: 24825316).
  4. Renoir T, Hasebe K, Gray L. Mind and body: how the health of the body impacts on neuropsychiatry. Front Pharmacol. 2013 Dec 18;4:158. (PMID: 24385966).
  5. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013 Apr 16;4:45. (PMID: 23596418).
  6. Wright DJ, Gray LJ, Finkelstein DI, Crouch PJ, Pow D, Pang T, Li S, Smith ZM, Francis PS, Renoir T, Hannan AJ. N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease. Hum Mol Genet. 2016 May 14. (PMID: 27179791)
  7. Rogers J, Vo U, Buret LS, Pang TY, Meiklejohn H, Zeleznikow-Johnston A, Churilov L, van den Buuse M, Hannan AJ, Renoir T. Dissociating the therapeutic effects of environmental enrichment and exercise in a mouse model of anxiety with cognitive impairment. Transl Psychiatry. 2016 Apr 26;6:e794. (PMID: 27115125)

Support us

Brain health affects all Australians.
You can support our research by making a donation or a bequest.

Newsletter

Latest breakthroughs, news, events & more.